- Home
- CLBT vs TNDM Comparison
CLBT vs TNDM Comparison
Compare CLBT & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLBT
- TNDM
- Stock Information
- Founded
- CLBT 1999
- TNDM 2006
- Country
- CLBT Israel
- TNDM United States
- Employees
- CLBT N/A
- TNDM N/A
- Industry
- CLBT Computer Software: Prepackaged Software
- TNDM Medical/Dental Instruments
- Sector
- CLBT Technology
- TNDM Health Care
- Exchange
- CLBT Nasdaq
- TNDM Nasdaq
- Market Cap
- CLBT 2.5B
- TNDM 2.7B
- IPO Year
- CLBT N/A
- TNDM 2013
- Fundamental
- Price
- CLBT $18.49
- TNDM $34.81
- Analyst Decision
- CLBT Strong Buy
- TNDM Buy
- Analyst Count
- CLBT 9
- TNDM 15
- Target Price
- CLBT $18.00
- TNDM $53.27
- AVG Volume (30 Days)
- CLBT 1.1M
- TNDM 1.3M
- Earning Date
- CLBT 11-06-2024
- TNDM 11-06-2024
- Dividend Yield
- CLBT N/A
- TNDM N/A
- EPS Growth
- CLBT N/A
- TNDM N/A
- EPS
- CLBT N/A
- TNDM N/A
- Revenue
- CLBT $362,488,000.00
- TNDM $796,002,000.00
- Revenue This Year
- CLBT $23.68
- TNDM $21.53
- Revenue Next Year
- CLBT $17.07
- TNDM $11.81
- P/E Ratio
- CLBT N/A
- TNDM N/A
- Revenue Growth
- CLBT 23.46
- TNDM 0.72
- 52 Week Low
- CLBT $6.37
- TNDM $13.82
- 52 Week High
- CLBT $18.73
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- CLBT 67.97
- TNDM 29.10
- Support Level
- CLBT $17.65
- TNDM $35.16
- Resistance Level
- CLBT $18.44
- TNDM $38.94
- Average True Range (ATR)
- CLBT 0.59
- TNDM 2.02
- MACD
- CLBT 0.06
- TNDM -0.58
- Stochastic Oscillator
- CLBT 90.62
- TNDM 7.89
About CLBT Cellebrite DI Ltd.
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.